Working… Menu

Contingency Management for Alcohol Use Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02135237
Recruitment Status : Completed
First Posted : May 9, 2014
Last Update Posted : November 1, 2019
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by (Responsible Party):
Sheila Alessi, UConn Health

Brief Summary:
Contingency management (CM) treatments are highly efficacious in improving outcomes of substance abusing patients. However, CM has rarely been applied to individuals with alcohol use disorders, primarily because of technological limitations in monitoring drinking. The Secure Continuous Remote Alcohol Monitor (SCRAMx®) is a new technology designed to continuously monitor alcohol consumption 24 hours a day for 7 days per week. The purpose of this study is to evaluate the efficacy of CM in reducing alcohol use using SCRAMx. In total, 120 alcohol abusing or dependent patients initiating outpatient treatment at community-based clinics will be randomly assigned to one of two conditions: standard care, or standard care plus CM with reinforcement based on results of SCRAMx readings. Compared with standard care, it is expected that CM will result in fewer drinking days and longer durations of continuous non-drinking days.

Condition or disease Intervention/treatment Phase
Alcohol Use Disorder Contingency Management Behavioral: Prize Contingency Management for Alcohol Abstinence Behavioral: Standard Care Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Contingency Management for Alcohol Use Disorders
Actual Study Start Date : January 2014
Actual Primary Completion Date : June 2019
Actual Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Alcohol
Drug Information available for: Ethanol

Arm Intervention/treatment
Active Comparator: Control Group
Standard Care
Behavioral: Standard Care
Experimental: Experimental Group
Standard Care plus Prize Contingency Management for Alcohol Abstinence
Behavioral: Prize Contingency Management for Alcohol Abstinence
The systematic reinforcement of desired behaviors and the withholding of reinforcement for undesired behaviors

Behavioral: Standard Care

Primary Outcome Measures :
  1. longest duration of abstinence from alcohol [ Time Frame: three months ]
    objective report of alcohol use as measured by SCRAMx device

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 18 years or older
  • current diagnosis of alcohol use disorder and self report of recent alcohol use
  • pass an informed consent quiz
  • agree to wear a SCRAMx monitor for 12 weeks
  • have a standard SCRAMx compatible phone line in their home or agree to attend the clinic weekly for brief research visits/downloads
  • agree to sign an off-campus property transfer form and return SCRAMx equipment

Exclusion Criteria:

  • serious, uncontrolled psychiatric illness
  • in recovery from pathological gambling
  • have an unstable address
  • intend to participate in activities incompatible with SCRAMx over the next 3 months
  • are wearing SCRAMx for legal purposes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02135237

Layout table for location information
United States, Connecticut
The Hospital of Central Connecticut at New Britain General
New Britain, Connecticut, United States, 06050
Farrell Treatment Center
New Britain, Connecticut, United States, 06051
United States, Massachusetts
Behavioral Health Network, Inc.
Springfield, Massachusetts, United States, 01104
Sponsors and Collaborators
UConn Health
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Layout table for investigator information
Principal Investigator: Sheila Alessi, Ph.D. UConn Health
Layout table for additonal information
Responsible Party: Sheila Alessi, Associate Professor, UConn Health Identifier: NCT02135237    
Other Study ID Numbers: 12-204H-2
R01AA021446 ( U.S. NIH Grant/Contract )
First Posted: May 9, 2014    Key Record Dates
Last Update Posted: November 1, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alcohol Drinking
Drinking Behavior
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders